Lihong He
Mayo Clinic
PharmacodynamicsEnhancerPharmacokineticsCancerInternal medicineDNA damageOncologyIonizing radiationChemistryIn vivoMdm2GlioblastomaAntibody-drug conjugateTemozolomideMelanomaGliomaDrugTumor growthTumor cellsCancer researchRadiation therapyDNA-PKcsMedicineCell cultureBiology
17Publications
3H-index
85Citations
Publications 17
Newest
#1Danielle M. Burgenske (Mayo Clinic)H-Index: 2
#2Surabhi Talele (UMN: University of Minnesota)H-Index: 1
Last. Gautham Gampa (UMN: University of Minnesota)H-Index: 7
view all 22 authors...
BACKGROUND Glioblastoma (GBM) is an incurable disease with few approved therapeutic interventions. Radiation therapy (RT) and temozolomide (TMZ) remain the standards of care. The efficacy and optimal deployment schedule of the orally bioavailable small-molecule tumor checkpoint controller lisavanbulin alone, and in combination with, standards of care were assessed using a panel of IDH-wildtype GBM patient-derived xenografts. METHODS Mice bearing intracranial tumors received lisavanbulin +/- RT +...
Source
#1Bianca Maria Marin (Mayo Clinic)H-Index: 1
#2Kendra A Porath (Mayo Clinic)H-Index: 1
Last. Jann N. Sarkaria (Mayo Clinic)H-Index: 70
view all 30 authors...
BACKGROUND Antibody drug conjugates (ADCs) targeting the epidermal growth factor receptor (EGFR), such as depatuxizumab mafodotin (Depatux-M), is a promising therapeutic strategy for glioblastoma (GBM) but recent clinical trials did not demonstrate a survival benefit. Understanding the mechanisms of failure for this promising strategy is critically important. METHODS PDX models were employed to study efficacy of systemic vs intracranial delivery of Depatux-M. Immunofluorescence and MALDI-MSI wer...
Source
#1Jianxiong Ji (Mayo Clinic)H-Index: 1
#2Emily L. Smith (Mayo Clinic)H-Index: 1
Last. Zeng Hu (Mayo Clinic)H-Index: 2
view all 22 authors...
Source
#1Rachael A. Vaubel (Mayo Clinic)H-Index: 9
#2Ann C. Mladek (Mayo Clinic)H-Index: 21
Last. Jann N. Sarkaria (Mayo Clinic)H-Index: 70
view all 13 authors...
Source
#1Gaspar J. Kitange (Mayo Clinic)H-Index: 29
#2Danielle M. Burgenske (Mayo Clinic)H-Index: 2
Last. Jann N. Sarkaria (Mayo Clinic)H-Index: 70
view all 10 authors...
Source
#1Shiv K. Gupta (Mayo Clinic)H-Index: 43
#2Ann C. Mladek (Mayo Clinic)H-Index: 21
Last. Jann N. Sarkaria (Mayo Clinic)H-Index: 70
view all 11 authors...
Despite aggressive treatment that involves surgery, radiation and temozolomide therapy, a significant morbidity from glioblastoma (GBM) recurrence highlights the pressing unmet medical need to develop effective novel therapies for GBM. Murine Double Minute 2 (MDM2) is an important regulator of the p53 tumor suppressor, which promotes cell cycle arrest and apoptosis in response to DNA damage. Here we have assessed the efficacy of RG7388, a purported brain penetrant MDM2-inhibitor, alone or combin...
Source
#1Jianxiong Ji (Mayo Clinic)H-Index: 1
#2Emily J. Smith (Mayo Clinic)H-Index: 2
Last. Jann N. Sarkaria (Mayo Clinic)H-Index: 70
view all 15 authors...
Radio-resistant properties of melanomas undermine benefit of radiation therapy (RT). DNA-dependent protein kinase (DNA-PKcs) is essential for the non-homologous end joining (NHEJ) mediated repair DNA double-strand break (DSB). We evaluated radio-sensitizing effects of M3814, a selective oral inhibitor of DNA-PKcs, in patient-derived xenografts (PDXs) of melanoma brain metastases. M3814 (≥300 nM) inhibited RT-induced (5 Gy) auto-phosphorylation of serine-2056 of DNA-PKcs in primary cultures of M1...
Source
#1Jiajia Chen (Mayo Clinic)
#2Shiv K. Gupta (Mayo Clinic)H-Index: 43
Last. Jann N. Sarkaria (Mayo Clinic)H-Index: 70
view all 11 authors...
The efficacy of standard radiation therapy (RT) in glioblastoma (GBM) is limited, and there is a strong rationale to develop effective radiosensitizing agents. ATM is a key regulator of DNA damage induced by RT, and small molecule ATM inhibitors have shown radio-sensitizing effects in cancer cells, and may improve radio-sensitivity in GBM. Here, we evaluated the brain penetrant ATM inhibitor AZD1390 in combination with RT in GBM cell lines and patient derived xenografts (PDXs). AZD1390 (30 nM an...
Source
#1Danielle M. Burgenske (Mayo Clinic)H-Index: 2
#2Ann C. Mladek (Mayo Clinic)H-Index: 21
Last. Jann N. Sarkaria (Mayo Clinic)H-Index: 70
view all 18 authors...
Lisavanbulin (LIS; BAL101553) is the prodrug of BAL27862, a microtubule-binding, tumor checkpoint controller and potential radiosensitizer. These studies evaluated optimal integration of LIS with standard of care radiation therapy (RT) and/or temozolomide (TMZ) using GBM PDX models. Distribution across the blood brain barrier was evaluated after a single 30 mg/kg oral LIS dose, and concentrations of the active metabolite BAL27862 were measured by liquid chromatography-tandem mass spectrometry. S...
Source
#1Susan Christine Massey (Mayo Clinic)H-Index: 7
#2Andrea Hawkins-Daarud (Mayo Clinic)H-Index: 16
Last. Kristin R. Swanson (Mayo Clinic)H-Index: 48
view all 20 authors...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.